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ABSTRACT 
A new HPLC method was developed for selective and simultaneous determination of of Teamazepam. The developed method is also applicable for the 
related substances determination in bulk drugs. The chromatographic separation was achieved on a Zorbax SB C-18, 4.6 x 250mm, and 5µ column. The 
mobile phase consisted of Acetonitrile and methanol (60:40, v/v) delivered at a flow rate of 2.0 mL min
−1. Buffers consisted of dissolve 5.22 g of dipotassium 
hydrogen orthophosphate in 1000 mL of water and add 2 mL of triethylamine, adjust pH to 3.0 with ortho phosphoric acid. The mobile phase was pumped at 
a flow rate 2.0 mL  per minute and  detector  of  UV at 245 nm. In the developed HPLC  method, the resolution  between Teamazepam and its  potential 
impurities, namely Imp-A, Imp-B, Imp-C, and Imp-G was found. Accuracy found by % recovery from 99.2-100.5 at 80.0% to 120.0% level and the linearity 
results for Teamazepam and its related compounds in the specified concentration calibration curves linear with coefficient of variation (r) not less than 0.99 
The drug was subjected to stress conditions of hydrolysis, oxidation, photolysis and thermal degradation. Considerable degradation was found to occur acid 
hydrolysis conditions. The stress samples were assayed against a qualified reference standard and the mass balance was found close to 95% - 105%. The 
developed RP-LC method was validated with respect to linearity, accuracy, precision and robustness. The validation was performed according to the current 
requirements as laid down in the ICH guidelines. 
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INTRODUCTION 
Temazepam  (marketed  under  brand  names  Normison, 
Temtabs, Euhypnos, Restoril, Remestan, Tenox, Temaze and 
Norkotral)  is  an  intermediate-acting  3-hydroxy 
benzodiazepine. It is generally prescribed for the short-term 
treatment  of  sleeplessness  in  patients  who  have  difficulty 
maintaining  sleep.  In  addition,  temazepam  has  anxiolytic 
(anti-anxiety),  anticonvulsant,  and  skeletal  muscle  relaxant 
properties
1-3. Temazepam was first synthesized in 1964, but it 
first  came  into  use  in  1969  when  its  ability  to  counter 
insomnia was realized
4.  By the late 1980s, temazepam was 
one of the most popular and widely prescribed hypnotics on 
the market and it became one of the most widely prescribed 
drugs. Temazepam is a hypnotic agent. In sleep laboratory 
studies,  temazepam  significantly  decreased  the  number  of 
nightly awakenings
5 but has the drawback of distorting the 
normal sleep pattern
6.  
Temazepam is officially indicated for severe insomnia and 
other  severe  or  disabling  sleep  disorders.  The  prescribing 
guidelines  in  the  UK  limit  the  prescribing  of  hypnotics  to 
two-to-four  weeks  due  to  concerns  of  tolerance  and 
dependence
7. 
Temazepam should not be used in pregnancy, as it may cause 
harm to the fetus. The safety and effectiveness of temazepam 
has  not  been  established  in  children;  therefore  temazepam 
should generally not be given to individuals under 18 years of 
age, and should not be used at all in children under 6 months 
old. Benzodiazepines also require special caution if used in 
the  elderly,  alcohol  or  drug-dependent  individuals  and 
individuals with comorbid psychiatric disorders
8.  
The smallest possible effective dose should be used in elderly 
or very ill patients, as there is a risk of apnea and/or cardiac 
arrest.  This  risk  is  increased  when  temazepam  is  given 
concomitantly  with  other  drugs  that  depress  the  central 
nervous system
9.  
Chronic  or  excessive  use  of  temazepam  may  cause  drug 
tolerance,  which  can  develop  rapidly
10,  so  this  drug  is 
therefore not recommended for long-term use. In 1979 the 
Institute of Medicine (USA) and the National Institute on 
Drug  Abuse  stated  that  most  hypnotics  lose  their  sleep-
inducing properties after about 3 to 14 days
11. In use longer 
than 1–2 weeks, tolerance will frequently develop towards 
the ability of temazepam to maintain sleep, so that the drug 
loses effectiveness
12. Some studies have observed tolerance 
to  temazepam  after as  little  as  one  week's  use
13.  Another 
study examined the short-term effects of the accumulation of 
temazepam over 7 days in elderly inpatients, and found that 
little  tolerance  developed  during  the  accumulation  of  the 
drug
14. Other studies examined the use of temazepam over 
six days and saw no evidence of tolerance
15,16.  
MATERIALS AND METHODS 
Reagents and Chemicals 
HPLC  grade  Acetonitrile  and  methanol,  triethylamine, 
anhydrous potassium dihydrogen orthophosphate and Ortho 
Phosphoric acid (85 %) from Merck Research Laboratories, 
India. 
Chromatographic conditions 
Chromatographic  system  consisted  of  a  Waters  Model 
Alliance 2489 separation module equipped with auto sampler 
Photodiode array ultraviolet (UV) detector. The data recorded 
using  empower  software.  A  gradient  HPLC  analytical 
column; Zorbax SB C-18, 4.6 x 250mm, particle size 5 μm; 
and detector of UV at 225 nm. 
Preparation of standard solution 
About  100  mg  of  Teamazepam  r  standard  was  transferred 
into a 50 mL volumetric flask. Dissolved in and diluted to 
volume  with  diluent  of  methanol.  Diluted  5.0  mL  of  this 
solution  to  10  mL  with  diluent  of  methanol.  Prepared  in 
duplicate. 
Validation of HPLC method 
In order to confirm method suitability during routine quality 
control use, the proposed method was checked critically for 
the following validation characteristics as per ICH guidelines. 
Linearity 
Linearity  for  Teamazepam  was  determined  in  the 
concentration range 80 to 120 % of working concentration of 
standard. The peak area responses were plotted against the D. Ramachndran et al. IRJP 2012, 3 (11) 
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corresponding  concentrations  and  the  r
2  values  were 
calculated. 
Precision 
System precision: The system precision was performed by 
analysing  system  suitability  standard  solution  six  times. 
Results  of  Peak  area  of  the  impurities.  The  peak  area 
variation observed for Teamazepam and impurities was less 
than 5.0 
Method  precision:  Six  samples  of  Teamazepam  were 
analyzed as per the method. Each named impurity and total 
impurities were calculated on these replicates. 
Intermediate precision or inter-day precision 
The intermediate or inter-day precision of the method was 
determined  by  six  replicate  analysis  of  Teamazepam  from 
sample, as per the proposed method by different instruments 
and (Waters Alliance 2489 and Shimadzu), by same analyst 
on different days. The average drug content and the % RSD 
were calculated in each case. 
Accuracy (recovery studies) 
Recovery  studies  were  performed  by  standard  addition 
method  at  three  levels  i.e.  80%,  100%  and  120%.  Known 
amounts  of  standard  Teamazepam  were  added  to  pre-
analyzed samples and they were subjected to proposed HPLC 
method. Results of recovery studies are shown in Table 1. 
Stability of analytical solution 
A sample solution of Teamazepam was prepared as per the 
proposed method. To this sample all known impurities were 
quantitatively spiked at specification limit concentration and 
stored  at  10°C.  The  sample  was  injected  into  the  system 
initially and at various time intervals. Sample solution spiked 
with impurities was found to be stable up to 1600 minutes at 
10°C. 
Robustness 
The robustness study was done by making small changes in 
the  optimized  method  parameters  as  indicated  in  Table  2. 
Results are also shown there. 
Ruggedness 
The ruggedness study was done by the two analysts by using 
the proposed method by same instrument on same day. The 
% RSD for each analyst for each drug was calculated. 
Evaluation of system suitability 
Inject blank (diluent), followed by reference solution in six 
times into the chromatograph and record the chromatograms. 
The  system  is  suitable  for  analysis,  if  and  only  if,  the 
resolution between Teamazepam and intermediate peaks not 
less than 2.0. The tailing factor for Teamazepam peak not 
more  than  2.0.  The  number  of  theoretical  plates  for 
Teamazepam peak not less than 3000. Inject sample solutions 
into the chromatograph and record the chromatograms. Note 
sown the area response of peaks eluting. Disregard the peaks 
due  to  blank.  The  retention  time  of  Teamazepam  peak  is 
about 14 minutes 
 
 
Table 1: Assay results of intermediate precision 
Sample  Analyst 1 - Day1  Analyst 2 - Day2  Bias 
Sample-1  99.4  99.9  -0.5 
Sample-2  99.2  99.9  -0.7 
Sample-3  99.6  99.4  +0.2 
Sample-4  99.2  99.7  -0.5 
Sample-5  99.3  99.5  -0.2 
Sample-6  99.5  99.9  -0.4 
% RSD  0.16  0.24   
 
Table 2: Result of recovery studies 
Drugs  Recovery 
levels 
Mean % of 
recovery 
% 
RSD 
Teamazepam  80 %  100.1  0.25 
100 %  100.5  0.15 
120 %  99.2  0.05 
 
Table 3: Robustness for Teamazepam 
Parameters  Actual  Low level  High level 
Flow variation  2.0 ml/min  1.8 ml/min  2.2 ml/min 
Column oven temperature  30
0C  28
0C  32
0C 
Buffer pH variation  3.0  2.8  3.2 
Buffer composition 
variation 
60:40  62:38  58:42 
RESULTS AND DISCUSSION 
In linearity study, the graphical representation of data proves 
that Teamazepam and linearity in the range of 0.16 mg/ml to 
0.24 mg/ml with r
2 value 0.9997. 
In system precision study, the % RSD for Teamazepam was 
found to be 0.12 respectively. The % RSD observed on the 
replicate indicates the precision of the system. 
In  method  precision  study,  the  mean  %  drug  content  for 
Teamazepam  was  found  to  be  99.2  %  and  99.6  % 
respectively. The % RSD for Teamazepam was found to be 
0.16.  The  results  indicate  that  the  method  is  validated  for 
method precision. No interference forms other components or 
excipient was found during determination. 
In intermediate or inter-day precision study, the mean % drug 
content  for  Teamazepam  found  to  be  99.2  and  99.9 
respectively. The % RSD for Teamazepam found to be 0.16 
and 0.24 respectively. There is no significant difference by 
same  analyst  by  different  instruments  on  different  day. 
Therefore  the  intermediate  or  inter-day  precision  of  the 
method can be considered to be acceptable as shown in table 
1.The  bias  in  assay  determination  for  each  parameter  less 
than ± 1.5. 
In  accuracy  or  recovery  studies,  the  results  are  shown  in 
Table  2.  The  overall  %  of  recovery  and  %  RSD  for 
Teamazepam in marketed formulation indicated that there is 
no  significant  difference  in  percentage  of  recovery. 
Therefore, accuracy of the method considered acceptable as it 
was well within 99.2 to 100.5 %. 
A sample solution of Teamazepam was prepared as per the 
proposed method. To this sample all known impurities were 
quantitatively spiked at specification limit concentration and 
stored  at  10°C.  The  sample  was  injected  into  the  system 
initially and at various time intervals. Sample solution spiked 
with impurities was found to be stable up to 1600 minutes at 
10°C. 
In  robustness  or  system  suitability  study,  there  was  no 
significant  impact  on  the  %  RSD  and  tailing  factor.  The 
results of the robustness study also indicated that the method 
is  robust  and  is  unaffected  by  small  variations  in  the 
chromatographic conditions. 
Degradation study 
Analyze the impurities and Teamazepam individually as per 
above method to verify the retention time. In order to assess 
the  stability  indicating  nature  of  the  HPLC  method, D. Ramachndran et al. IRJP 2012, 3 (11) 
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Teamazepam samples were stressed by acid, base, hydrogen 
peroxide, heat and UV radiation. The degraded samples are 
analyzed using a photodiode-array detector. 
Sample Preparation 
Accurately  weigh and transfer about 50.0 mg of substance 
into  a  100  mL  volumetric  flask,  dissolve  in  and  dilute  of 
methanol.  Dilute  5.0  mL  of  this  solution  to  10  mL  with 
diluents. 
Acid hydrolysis, Base hydrolysis and Oxidation 
At room temperature accurately weigh and transfer about 100 
mg of substance into a 100 mL volumetric flask, dissolved in 
and diluted to volume with diluents methanol. From this take 
5.0  mL  of  this  solution  was  transferred  into  a  10  mL 
volumetric flask and added 0.2 mL of 1N hydrochloric acid 
solution. The solutions were kept at room temperature for 3 
hours, then neutralized with 0.2 mL of 1N sodium hydroxide 
solution  and  diluted  to  10  mL  with  diluents  methanol.  At 
600C one solution was prepared by transferring about 100 
mg of substance into a 50 mL volumetric flask, dissolved in 
and diluted to volume with diluent methanol. 5.0 mL of this 
solution was transferred into a 10 mL volumetric flask and 
added 0.2 mL of 1N hydrochloric acid solution. The solutions 
were kept at 600C for 3 hours, then neutralized with 0.2 mL 
of 1N sodium hydroxide solution and diluted to 10 mL with 
diluent of methanol. 
At room temperature four solutions was prepared individually 
by  transferring  about  100  mg  of  substance  into  a  50  mL 
volumetric  flask,  dissolved  in  and  diluted  to  volume  with 
diluents methanol.  5.0  mL  of  this  solution  was  transferred 
into  a  10  mL  volumetric  flask  and  added  0.2  mL  of  1N 
sodium hydroxide solution. The solutions were kept at room 
temperature for 3 hours, 6 hours, 12 hours and 24 hours, then 
neutralized with 0.2 mL of 1N hydrochloric acid solution and 
diluted  to  10  mL  with  diluent  of  methanol.  At  600C  four 
solutions was prepared individually by transferring about 100 
mg of substance into a 50 mL volumetric flask, dissolved in 
and diluted to volume with diluents methanol. 5.0 mL of this 
solution was transferred into a 10 mL volumetric flask and 
added  0.2  mL  of  1N  sodium  hydroxide  solution.  The 
solutions were kept at 600C for 3 hours, 6 hours, 12 hours 
and  24  hours,  then  neutralized  with  0.2  mL  of  1N 
hydrochloric acid solution and diluted to 10 mL with diluent 
of methanol.  
At room temperature four solutions was prepared individually 
by  transferring  about  100  mg  of  substance  into  a  50  mL 
volumetric flask, dissolved in and diluted to 100 mL diluent 
of methanol. 5.0 mL of this solution was transferred into a 10 
mL volumetric flask and added 0.2 mL of 5% of hydrogen 
peroxide  solution.  The  solutions  were  kept  at  room 
temperature for 3 hours, 6 hours, 12 hours and 24 hours and 
diluted  to  10  mL  with  diluents  of  methanol.At  600C  four 
solutions was prepared individually by transferring about 100 
mg of substance into a 50 mL volumetric flask, dissolved in 
and diluted to 100 mL diluent of methanol. 5.0 mL of this 
solution was transferred into a 10 mL volumetric flask and 
added  0.2  mL  of  5%  of  hydrogen  peroxide  solution.  The 
solutions were kept at 600C for 3 hours, 6 hours, 12 hours 
and 24 hours and diluted to 10 mL with diluents of methanol. 
Heat degradation, UV degradation 
Four  solutions  was  prepared  individually  by  transferring 
about 100 mg of substance into a 50 mL volumetric flask, 
dissolved in and diluted to 100 mL diluent of methanol. 5.0 
mL of this solution was transferred into a 10 mL volumetric 
flask. The solutions were kept at 600C for 3 hours, 6 hours, 
12 hours and 24 hours and diluted to 10 mL with diluents of 
methanol. 
UV degradation was carried out by accurately weighed and 
transferred  about  50.0  mg  of  substance  into  a  100  mL 
volumetric  flask,  dissolve  in  and  diluted  to  volume  with 
diluents of methanol. Taken 5.0 mL of above solution into a 
10 mL volumetric flask and exposed to an integrated near 
Ultra  violet  energy  (UV  light  )  of  not  less  than  200 
watt/square  meter  and  then  diluted  to  10  mL  with  the 
diluents. 
 
CONCLUSION 
Hence,  it  can  be  concluded  that  the  newly  developed  RP-
HPLC method was found to be simple, rapid, cost-effective, 
linear, accurate, precise and robust over the specified range; 
and selective for Teamazepam without any interference from 
other components or additives. This method can be employed 
conveniently, reliably and successfully for the estimation of 
Teamazepam for routine quality control and stability studies.  
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